Myopathy in patients with Waldenström‘s macroglobulinemia.
A case study and an overview of autoimmune expressions of type IgM monoclonal immunoglobulins

Czech version

Authors: Zdeněk Adam ¹; Jarmila Kissová ¹; Luděk Pour ¹; Marta Krejčí ¹; Eva Ševčíková ¹; Renata Koukalová ²; Zdeňka Čermáková ³; Marta Černá ⁴; Zdeněk Král ¹; Jiří Mayer ¹
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ¹; Oddělení nukleární medicíny, pracoviště pozitronové emisní tomografie, Masarykův onkologický ústav, Brno prim. MUDr. Zdeněk Řehák, Ph. D. ²; Oddělení klinické biochemie FN Brno, pracoviště Bohunice, a Katedra laboratorních metod LF MU, Brno, přednosta doc. MUDr. Milan Dastych, CSc., MBA ³; Hematologicko transfuzní oddělení Uherskohradišťské nemocnice, a. s., Uherské Hradiště, prim. MUDr. Marta Černá ⁴
Published in: Vnitř Lék 2015; 61(9): 821-828
Category: Case Reports

Overview

Waldenström‘s macroglobulinemia which was manifested by muscle pain and anemia. The female patient had suffered from back pain for about 3 years before she came to our clinic. In the last year pain in the muscles of the upper and lower extremities developed in addition to back pain. This led to the suspicion of polymyositis. However this was not confirmed by a special examination. The patient was diagnosed with clearly established infiltration of lymphoplasmacytic lymphoma and 10.8 g/l of type IgM monoclonal immunoglobulin in the bone marrow. Serum myoglobin levels and serum CK activity were repeatedly significantly increased. Therefore the treatment with anti-CD20 monoclonal antibody (Mabthera) 375 mg/m² i. v. was started, administered once a month, with cyclophosphamide 500 mg/m² i. v. on days 1 and 15 of a 28-day cycle, and dexamethasone 20 mg from 1st through to 4th days and 15th through to 18th days of the treatment cycle. There were 8 cycles planned. Already after a 5th cycle, the disappearance of monoclonal immunoglobulin (negative immunofixation), normalisation of myoglobin and CK values and significant relief from muscle pain were achieved. The hemoglobin concentrations before treatment were significantly reduced, while they were normalised after treatment. After 5 cycles, the complete remission of Waldenström‘s disease was reached according to biochemical parameters, and normalisation of the serum myoglobin and creatine kinase levels was achieved.

Key words:
Mabthera – myopathy – type IgM monoclonal immunoglobulin – Waldenström‘s macroglobulinemia

Sources

1. Dighiero G, Guilbert B, Fermand JP et al. Thirty-six human monoclonal immunoglobulins with antibody activity against cytoskeleton proteins, thyroglobulin, and native DNA: immunologic studies and clinical correlations. Blood 1983; 62(2): 264–270.

2. Avrameas S, Guilbert B, Dighiero G. Natural antibodies against tubulin, actin myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenström’s macroglobulinemia may express similar antibody specificities. Ann Immunol (Paris) 1981; 132C(2): 231–236.

3. Al-Lozi M, Pestronk A. Organ-specific autoantibodies with muscle weakness. Curr Opin Rheumatol 1999; 11(6): 483–488.

4. Bulikova A, Smejkal P, Zavřelová J at al. Získané inhibitory krevního srážení. Interní medicína pro praxi 2008; 10(7): 336–339.

5. Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000; 15(2): 173–178.

6. Carlizzi G, Ciarla MV, Diluzio A et al. Autoantibodies in patients with monoclonal gammopathies. Ann N.Y. Acad Sci 2007; 1107: 206–211.

7. Stone MJ, McElroy A, Pestronk P et al. Human monoclonal macroglobulins with anbody activity. Semin Oncol 2003; 30(2): 318–324.

8. Stone MJ, Marlini V, Pascual P. Autoantibody activity in Waldenström´s macroglobulinaemia. Clin Lymphoma 2005; 5(4): 225–229.

9. Antienza J, Bockorn B, Dadla A et al. Inflammatory and immune-releated condition associated with Waldenström´s macroglobulinemia. A single center experience. Leukemia and Lymphoma 2015; 56(4): 1179–1180.

10. Ansell SM. Waldenström Macroglobulinemia and autoimmunity: what´s the connection? Leukemia Lymphoma 2015; 56(4): 845–846.

11. Jonsson V, Kierkegaard A, Salling S et al. Autoimmunity in Waldenström´s macroglobulinemia. Leukemia Lymphoma 1999; 34(3–4): 373–379.

12. Christenson W, Dacie J. Serum proteins in acquired hemolytic anemia (autoantibody type). Brit J Haematol 1957; 3(2): 153–164.

13. Adam Z, Pejchalová A, Chlupová G. Nemoc chladových aglutininů nereagující na léčbu glukokortikoidy a na léčbu rituximabem. Jaký postup zvolit pro třetí linii léčby? Popis případu a přehled literatury. Vnitř Lék 2013; 59(9): 828–840.

14. Kritzman J, Kunkel H, McCarthy J et al. Studie of a Waldenström-type macroglobulinemia with revmatoid factor properties. J Lab Clin Med 1961; 57: 905–917.

15. Adam Z, Králová E. Kryoglobulinémie – první příznak mnohočetného myelomu. Klin Onkol 1992; 5(5): 147–148.

16. Husa P, Adam Z, Husová E et al. Léčba chronické infekce virem hepatitidy C pegylovaným interferonem a ribavirinem u pacienta se smíšenou kryoglobulinémií. Vnitř Lék 2005; 51(2): 238–243.

17. Dellagi K, Brouet J Danon F. Gross idiotype antigens among monoclonal imunoglobulin M from patients with Waldenström´s macroglobulinemia and polyneuropathy. J Clin Incest 1979; 64(5): 1530–1534.

18. Adam Z, Šmardová J, Ščudla. V Waldenströmova makroglobulinemie – klinické projevy, diferenciální diagnostika a prognóza nemoci. Vnitř Lék 2007; 53(12): 1325–1337.

19. Adam Z, Pour L, Krejčí M et al. Poškození ledvin při mnohočetném myelomu a dalších monoklonálních gamapatiích. Vnitř Lék 2008; 54(9): 847–861.

20. Adam Z, Krejčí M, Pour L et al. Schnitzlerův syndrom – popis čtrnáctiletého průběhu nemoci a přehled informací o této nemoci. Vnitř Lék 2008; 54(12): 1140–1153.

21. Adam Z, Feit J, Krejčí M et al. IgA pemphigus provázející mnohočetný myelom vymizel při léčbě bortezomibem (Velcade), cyklofosfamidem a dexametazonem. Popis případu a přehled literatury. Vnitř Lék 2009; 55(10): 981–991.

22. Adam Z, Zahradová L, Krejčí M et al. Difuzní plošná normolipemická xantomatóza a nekrobiotický xantogranulom, asociované s monoklonální gamapatií – přínos PET-CT pro stanovení rozsahu nemoci a zkušenosti s léčbou. Popis dvou případ a přehled literatury. Vnitř Lék 2010; 56(11): 1159–1168.

23. Adam Z, Szturz P, Pour L et al. Kožní projevy monoklonálních gamapatií, zkušenosti jednoho pracoviště. Čes Dermatoven 2011; 1(2): 30–37.

24. Szturz P, Adam Z, Vašků V et al. Complete remission of multiple myeloma associated sclerodema after bortezomib-based treatment. Leuk Lymphoma 2013; 54(6): 1324–1326.

25. Mak WM, Chen PL, Lee K. Misleading hypercalcaemia in a patient with Waldenstrom’s macroglobulinaemia. Br J Biomed Sci 2011; 68(4): 210–212.

26. Elfatih A, Anderson NR, Fahie-Wilson MN et al. Pseudo-pseudohypercalcaemia, apparent primary hyperparathyroidism and Waldenström’s macroglobulinaemia. J Clin Pathol 2007; 60(4): 436–437.

27. Side L, Fahie-Wilson MN, Mills MJ. Hypercalcaemia due to calcium binding IgM paraprotein in Waldenström’s macroglobulinaemia. J Clin Pathol 1995; 48(10): 961–962.

28. al-Lozi MT, Pestronk A, Yee WC et al. Myopathy and paraproteinemia with serum IgM binding to a high-molecular-weight muscle fiber surface protein. Ann Neurol 1995; 37(1):41–46.

29. Bakri K, Haydar AA, Davis J et al. Waldenström’s macroglobulinaemia presenting as isolated epistaxis: a common complaint but a rare cause. Int J Clin Pract 2004; 58(1): 81–82.

30. Deconinck N, Laterre EC, Van den Bergh PY. Adult-onset nemaline myopathy and monoclonal gammopathy: a case report. Acta Neurol Belg 2000; 100(1): 34–40.

31. Eymard B, Brouet JC, Collin H et al. Late-onset rod myopathy associated with monoclonal gammopathy. Neuromuscul Disord 1993; 3(5–6): 557–560.

32. Islam A, Myers K, Cassidy DM et al. Muscle Involvement in Multiple Myeloma: Report of a Patient Presenting Clinically as Polymyositis. Hematology 1999; 4(2):123–125.

33. Keller CE, Hays AP, Rowland LP et al. Adult-onset nemaline myopathy and monoclonal gammopathy. Arch Neurol 2006; 63(1): 132–134.

34. Bockorny B, Atienza J, Dasanu CA. Autoimmune manifestation in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2014; 14(6): 456–549.

35. Adam Z, Hájek R, Krejčí M et al. Diagnostika a léčba Waldenströmovy makroglobulinémie. Transfuze a hematologie dnes 2014; 20(Suppl): 7–22.

36. Dimopoulos MA, Gastritis E, Owen RG et al. Treatment recommendation for patients with Waldenström macroglobulinemia and releated disorders. Blood 2014; 124(9): 1404–1411.

37. Castillo JJ, Olszewski AJ, Kanan S et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 2015; 169(1): 81–89.